The *Yersinia enterocolitica* Invasin Protein Promotes Major Histocompatibility Complex Class I- and Class II-Restricted T-Cell Responses

O. T. Bühler, C. A. Wiedig, Y. Schmid, G. A. Grassl, E. Bohn, and I. B. Autenrieth*

Institut für Medizinische Mikrobiologie und Hygiene, Universitätssklinikum Tübingen, D-72076 Tübingen, Germany

Received 17 February 2006/Returned for modification 30 March 2006/Accepted 20 April 2006

*Yersinia enterocolitica* invasin (Inv) protein confers internalization into and expression of proinflammatory cytokines by host cells. Both events require binding of Inv to β1 integrins, which initiates signaling cascades including activation of focal adhesion complexes, Rac1, mitogen-activated protein kinase, and NF-κB. Here we tested whether Inv might be suitable as a delivery molecule and adjuvant if used as a component of a vaccine. For this purpose, hybrid proteins composed of Inv and ovalbumin (OVA) were prepared, applied as a coating to microparticles, and used for vaccination. Fusion of OVA to Inv did not significantly disturb the ability of Inv to promote host cell binding, internalization, and interleukin-8 (IL-8) secretion when applied as a coating to microparticles. The microparticles were used for vaccination of mice adoptively transferred with OVA-specific T cells from OT-1 or DO11.10 mice. Administration of OVA-Inv-coated microparticles induced OVA-specific T-cell responses. OVA-specific CD4 T cells produced both gamma interferon (IFN-γ) and IL-4 as determined by enzyme-linked immunosorbent assay. Likewise, pronounced OVA-specific CD8 T-cell responses associated with IFN-γ production were observed. Together, these results suggest that Inv might be an attractive tool in vaccination as it confers both host cell uptake and adjuvant activity by engagement of β1 integrins of host cells, which leads to CD4 as well as CD8 T-cell responses.

*Yersinia enterocolitica* is a gram-negative, predominantly extracellularly located pathogen that causes food-borne acute or chronic gastrointestinal diseases. The pathogenicity of *Y. enterocolitica* depends on a virulence plasmid encoding pathogenicity factors such as secreted proteins (Yops) which by means of the type III secretion system are translocated directly into the cytosol of the host cells or the outer membrane protein YadA (9–12). In addition, several chromosome-encoded factors including yersiniabactin, invasin (Inv) (46, 47), SodA (51), and Irp-1 (51) promote the pathogenicity of *Y. enterocolitica*.

*Yersinia* Inv has been demonstrated to bind to αβ1 integrin heterodimers of host cells (29, 35). Upon clustering of integrins Inv activates signaling cascades. One signaling pathway causes activation of components of focal adhesion complexes including Src, focal adhesion kinase, and cytoskeletal proteins, leading to the formation of pseudopods that engulf the bacteria into the host cell (2, 3). A second pathway including activation of Rac1, NF-κB, and mitogen-activated protein kinase leads to production of proinflammatory cytokines (20, 56, 63).

*Y. enterocolitica* is taken up by M cells within the follicle-associated epithelium of Peyer’s patches (22, 23). The *Yersinia* Inv protein has been demonstrated to play an important role in this process as M cells, but not enterocytes, expose β1 integrins at their apical/luminal side, which upon engagement by Inv promotes translocation of *Y. enterocolitica* (57). Infection of mice with an Inv-deficient *Y. enterocolitica* mutant strain results in delayed initiation of the infection process although the 50% lethal dose of this mutant is unaltered (47, 48). Subsequently to translocation via M cells, yersiniae colonize the Peyer’s patches and may eventually disseminate to lymph nodes, liver, lung, and spleen. Immunohistological analyses suggest that innate host defense mechanisms are involved in control of *Yersinia* in Peyer’s patches (5). In addition, clearance of infection involves the activation of an adaptive immune response including CD8+ and CD4+ T helper 1 cells (6–8, 17, 42).

Attenuated *Yersinia* strains, created by targeted disruption of virulence-associated genes, have been demonstrated to be suitable as live carrier vaccines. In fact, YadA-, YopH-, or SodA-deficient *Y. enterocolitica* mutant strains turned out to be safe even in immunocompromised hosts (15). Moreover, such strains can induce T- and B-cell responses in vaccinated hosts. In previous studies, immunization experiments with various attenuated *Y. enterocolitica* and *Yersinia pseudotuberculosis* strains as carriers for heterologous antigens induced protective immune responses against challenge with, e.g., cholera toxin or *Listeria monocytogenes* in mice (52, 53, 59). In fact, delivery of heterologous antigens via the type III secretion system may induce both CD4 and CD8 T-cell responses in mice. More recent analysis, however, indicated that ovalbumin (OVA)-specific CD4 T-cell responses are not significantly induced upon delivery of OVA along with YopE (64).

In this study we used another *Yersinia* component as a targeting and delivery system of a vaccine. To induce optimal immune responses, antigens have to be administered along with an adjuvant. The Inv protein might exert all these functions. In fact, the Inv protein promotes host cell targeting via β1 integrins followed by internalization as well as inflammatory host cell reactions including production of chemokines. Therefore, we used the Inv protein fused to OVA as an antigen to create microparticles for vaccination of mice. Microparticles were used according to previous observations that in contrast...
to soluble Inv (unpublished data). Inv applied as a coating to microparticles elicits a proinflammatory response and is internalized by host cells (14, 56). The data presented demonstrate that by this means both CD4 and CD8 T-cell responses can be enhanced.

MATERIALS AND METHODS

DNA constructs. A part of the oval gene encoding 108 amino acids (aa 248 to 355) was amplified from pCI-2/OVA by PCR using the forward primer 5′-GG ATCCGATGACTGGTCCGCAGTGCAC′-3′ (BamHI restriction site underlined) and the reverse primer 5′-GGATTCCAGAGGACCTGGACGACTACCAC′-3′ (EcoRI restriction site underlined). The oval fragment was cloned using the Zero Blunt TOPO PCR cloning kit (Invitrogen, Karlsruhe, Germany), digested with EcoRI and BamHI, and cloned into pGEX-4T-3 expression vector (Amersham Biosciences, Freiburg, Germany) and pln397 (56), resulting in pOVA108 and pOVA-Inv397, respectively.

Expression and purification of fusion proteins. Escherichia coli BL21 harboring pGEX-4T-3, pln397, pOVA108, or pOVA-Inv397 was grown at 27°C in yeast extract tryptone medium to an optical density at 600 nm of 0.8 to 0.9. Expression of glutathione S-transferase (GST) and GST fusion proteins was induced with IPTG (isopropyl-β-D-thiogalactopyranoside) at a final concentration of 0.2 mM. Cells were grown for 4 additional hours before being harvested by centrifugation and stored at 4°C. Cells were resuspended in STE buffer (25 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM EDTA) containing lysozyme (2 mg/ml), bovine serum albumin and stored at 4°C. Coupling efficiency and molecular weight of coated proteins were checked by SDS-PAGE. Before use, the microparticles were resuspended in 0.3 M NaCl. Antibiotics and streptomycin (100 μg/ml) were added and incubation was continued at a temperature of 25°C for another hour. Then microparticles were washed in PBS containing 1 mg/ml bovine serum albumin and stored at 4°C. Coupling efficiency and integrity of coated proteins were checked by SDS-PAGE. Before use, the microparticles were resuspended in PBS, pH 7.0.

Cell culture and stimulation protocols. Human HeLa cervical epithelial cells (ATCC CCL-21) and mouse spleen cells were grown in RPMI 1640 (Biochrom, Berlin, Germany) and 10% heat-inactivated fetal calf serum (Gibco, Singapore, Taufkirchen, Germany) supplemented with 2 mM l-glutamine (Invitrogen, Karlsruhe, Germany) in a humidified 5% CO2 atmosphere at 37°C. For primary cells the medium was additionally supplemented with penicillin (100 U/ml) (Biochrom), streptomycin (100 μg/ml) (Biochrom), 0.05 mM 2-mercaptoethanol (Sigma), 1 mM sodium pyruvate (Biochrom), and 1% (vol/vol) nonessential amino acids (Biochrom). HeLa cells (1 × 10^7) were seeded in a 24-well tissue culture plate (Nunc, Nobschaden, Germany) and grown overnight. Confluent monolayers of cells were incubated with protein-coated microparticles with a ratio of 4,000 microparticles/cell for 2 h. After removal of the medium, cultures were washed three times with PBS, fresh medium was added, and incubation was continued for an additional 6 h. The amount of interleukin-8 (IL-8) secreted by the HeLa cells into the supernatant was determined by enzyme-linked immunosorbent assay (ELISA). Spleen cells from mice 5 days after immunization were homogenized and adjusted to a concentration of 1.5 × 10^6 or 10 × 10^6 cells/ml, distributed into a 24-well plate, and restimulated with 1 or 10 μg/ml of the respective ovalbumin-peptide OVA252-319 or OVA257-264 (SINFEKL) for 3 days. The amount of cytokines secreted by the restimulated spleen cells into the supernatant was determined by ELISA.

Cytokine ELISA. ELISAs were performed in Maxisorb-ELISA plates (Nunc) to determine the amount of secreted cytokines in the supernatant. IL-8 secreted by HeLa cells was detected as previously described (55) with optimal concentrations of a mouse anti-IL-8 monoclonal antibody (BD Pharmingen, Heidelberg, Germany) and a biotinylated mouse anti-IL-8 (BD Pharmingen) as detection antibody. Gamma interferon (IFN-γ) secretion was determined by using a capture ELISA including anti-IFN-γ monoclonal antibody (AN18.27.24) and biotin-labeled anti-IFN-γ monoclonal antibody (RA82A) described previously (4). Cytokine concentrations were calculated from the straight-line portion of a standard curve using recombinant human IL-8 (BD Pharmingen) or recombinant mouse IFN-γ (Bender, Vienna, Austria). The amount of secreted IL-4 was determined using the BD OptEIA Set mouse IL-4 kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer’s instructions.

Immunofluorescence microscopy. HeLa cells (5 × 10^4) were seeded on coverslips in a 24-well tissue culture plate (Nunc) and grown overnight. Semiconfluent monolayers of cells were incubated with protein-coated microparticles with a ratio of 100 microparticles/cell for 1 h to allow adherence and internalization. After removal of the medium, cultures were washed three times with PBS, fixed with 3.75% paraformaldehyde (Sigma), and blocked with 1% fetal calf serum in PBS. Extracellular microparticles were stained with polyclonal rabbit anti-Inv antibodies (diluted 1:100) (fusion proteins containing Inv397) or polyclonal goat anti-GST antibodies (Amersham Biosciences) (diluted 1:100) (protein without Inv397), followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit or donkey anti-goat antibodies (Dianova, Hamburg, Germany). After permeabilization with 2% Triton X-100 in PBS and blocking, intracellularly located microparticles were stained with the same primary antibodies as were the extracellular microparticles, followed by Cy5-conjugated goat anti-rabbit or rabbit anti-goat antibodies, respectively. F-actin was stained by tetramethyl rhodamine isothiocyanate-conjugated phalloidin (Sigma). The immunofluorescence images were obtained with a Leica DM RE microscope (Leica, Bensheim, Germany).

Immunization of mice. Eight- to 10-week-old female C57BL/6 and BALB/c (Harlan Winkelmann, Boreham, Germany), transgenic DO11.10 (40), and OT-1 (25) mice were kept in individually ventilated cages (Tecniplast, Italy) under specific-pathogen-free conditions. Transgenic DO11.10 mice (BALB/c background) express the mouse α- and β-chain T-cell receptor (TCR) that pairs with the CD4 co-receptor and which is specific for chicken ovalbumin peptide OVA252-319 (OVA252-319 peptide) in the context of M5 (class II restricted). Transgenic OT-1 mice (C57BL/6 background) express a TCR which pairs with the CD8 co-receptor and which is specific for chicken OVA257-264 in the context of K^b (class I restricted). Sterile food and water were provided ad libitum. Three mice per group were immunized by intraperitoneal administration of 2 × 10^10 microparticles coated with 90 to 150 μg protein.

Adoptive transfer of T cells. Spleen cells from DO11.10 mice were stained with anti-CD4-phycoerythrin (PE) and anti-CD8-PE (BD Pharmingen) antibodies and spleen cells from OT-1 mice were stained with anti-Vα2 TCR-FITC (49) (BD Pharmingen) and anti-CD8-PE (BD Pharmingen) antibodies and analyzed on a FACS Calibur flow cytometer (BD Biosciences) to determine the number of transgenic T cells. Spleen cells derived from DO11.10 mice or OT-1 mice containing 5 × 10^4 T cells were injected in a volume of 200 μl PBS into the tail vein of BALB/c or C57BL/6 mice, respectively.

Analysis of in vivo frequency of transgenic OVA-specific T cells. Three days after the adoptive transfer of T cells, 2 × 10^10 GST fusion protein-coated microparticles were injected intraperitoneally, and 5 days later the mice were sacrificed. The spleens were aseptically removed and homogenized. An aliquot of approximately 1 × 10^6 cells was stained with anti-DO11.10 clonotypic TCR-FITC (clone KJ1-26) (24) (BD Pharmingen) and anti-CD4-phycocerythrin (PE) antibodies (BD Pharmingen) and spleen cells from OT-1 mice were stained with anti-Vα2 TCR-FITC (49) (BD Pharmingen) and anti-CD8-PE (BD Pharmingen) antibodies and analyzed on a FACSCalibur flow cytometer (BD Biosciences) to determine the number of transgenic T cells. Spleen cells derived from DO11.10 mice or OT-1 mice containing 5 × 10^4 T cells were injected in a volume of 200 μl PBS into the tail vein of BALB/c or C57BL/6 mice, respectively.

Analysis of cytokine production in T cells by flow cytometry. For staining of intracellular IFN-γ, 1.5 × 10^6 spleen cells from immunized mice were seeded into a 24-well tissue culture plate. All samples were restimulated with 1 μg/ml of the respective OVA peptide. Two hours after addition of stimuli, monensin (BD Pharmingen) was added for 4 h to stop cytokine secretion. After blocking of Fc receptors and permeabilization, intracellular staining was performed using allophycocyanin-conjugated anti-IFN-γ antibodies (BD Pharmingen) and the reagents provided with the Cytofix/Cytoperm Plus kit (BD Pharmingen) following the manufacturer’s instructions. Staining of cell surface markers was done before permeabilization as described above.

Statistics. Data shown in the figures are from representative experiments. Comparable results were obtained in additional experiments. Differences be-
RESULTS

Construction of fusion proteins and coating of microparticles. In order to investigate the ability of *Y. enterocolitica* Inv protein to function as an adjuvant and targeting molecule for vaccination, we constructed a fusion protein of the C-terminal 397 amino acids of Inv with a part of OVA consisting of 108 amino acids comprising dominant T- and B-cell epitopes (data not shown). To accomplish this, an ova gene fragment encoding aa 248 to 355 was amplified from the plasmid pCI-2/OVA and ligated into the plasmid pmv397 carrying a part of the inv gene corresponding to the C-terminal 397 aa, resulting in the plasmid pOVA-Inv397. The plasmids described in Materials and Methods were introduced into *E. coli* BL21, and the proteins (GST, GST-Inv397, GST-OVA, and GST–OVA-Inv397) were expressed and purified (data not shown). Subsequently, these proteins were applied as a coating to microparticles and the amount of protein bound to the microparticles was estimated by SDS-PAGE by comparison with a bovine serum albumin standard (data not shown). About 300 to 500 μg of protein was detectable per ml of a suspension containing 6.7 × 10^{10} microparticles. In the following vaccine experiments, each mouse was immunized with 300 μl containing 2 × 10^{10} microparticles with 90 to 150 μg of fusion protein. To estimate the LPS contamination of the protein preparations, the LPS concentration was measured using a *Limulus* amoebocyte lysate assay. LPS concentrations in the different protein preparations ranged from 50 to 100 ng LPS per 2 × 10^{10} microparticles.

In vitro characterization of protein-coated microparticles. To elucidate whether the OVA protein impairs the Inv protein in its functions which are relevant for vaccination, namely, (i) stimulation of internalization and (ii) triggering proinflammatory host cell reactions via binding to β1 integrins, we performed in vitro experiments as previously published (56). HeLa cells were incubated for 1 h with microparticles coated with GST, GST-Inv397, GST-OVA, or GST–OVA-Inv397, and adhesion as well as internalization of microparticles was analyzed. Immunofluorescence microscopy showed that microparticles coated with GST or GST-OVA did not significantly adhere to HeLa cells and thus were not significantly internalized (Fig. 1). In contrast, microparticles coated with GST-Inv397 or GST–OVA-Inv397 efficiently adhered to and were internalized by HeLa cells (Fig. 1).

Next, IL-8 was determined by ELISA in culture supernatants of HeLa cells exposed to microparticles. The data indicate that Inv-coated microparticles induce IL-8 production of HeLa cells as previously reported (56). GST–OVA-Inv397-coated microparticles induced about 75% of IL-8 levels compared with GST-Inv397 microparticles but twofold-higher IL-8 levels than stimulation with GST-OVA108-coated microparticles or medium (Fig. 2). These experiments show that the OVA fragment fused to Inv does not significantly impair the ability of Inv to confer internalization and IL-8 production by host cells and thus maintains the putative targeting and adjuvant activity of Inv.

OVA-specific CD4 T-cell responses after immunization with OVA-Inv-coated microparticles. To determine the ability of Inv to induce T-helper cell responses against OVA, we analyzed the number of OVA-specific CD4 T cells upon adoptive transfer of OVA-specific T cells into mice prior to immunization with microparticles. Naive BALB/c mice received OVA-specific splenic T cells from transgenic DO11.10 mice (40) and were immunized 3 days later with 2 × 10^{10} microparticles coated with fusion proteins. Five days later, the frequency of transgenic CD4 T cells out of splenic CD4 T cells was analyzed by flow cytometry (Fig. 3). CD4 T-cell responses were not enhanced over background levels by immunization with Inv397.
microparticles (1.2% specific T cells versus 1.3% in PBS controls). Administration of OVA-coated microparticles increased the proportion of OVA-specific CD4 T cells almost threefold (3.8% specific T cells), but significantly higher numbers (8.9%) could be detected when OVA-Inv397-coated microparticles were administered. From these data we can conclude that OVA-Inv-coated microparticles induce significant OVA-specific CD4 T-cell responses in mice.

Cytokine production by OVA-specific CD4 T cells. To address the type of CD4 T-cell response obtained by immunization with OVA-Inv397 microparticles, spleen cells were isolated from mice at day 5 after immunization and cultured for another 3 days in the presence or absence of OVA323-339 peptide. The supernatants were analyzed by ELISA for IFN-γ and IL-4. We observed significantly higher IFN-γ production after immunization with OVA-Inv397 microparticles than after that with the OVA controls (24 ng/ml versus 10 ng/ml) or the other controls (Fig. 4). Even in the absence of additional OVA antigen in the in vitro cultures, significant IFN-γ levels were found in the cultures of spleen cells from OVA-Inv397-immunized mice. Moreover, we observed a profound IL-4 response by spleen cells from mice immunized with OVA-Inv397 microparticles (80 pg/ml) (Fig. 4). This response was significantly higher than that of controls (10 to 20 pg/ml) including spleen cells from mice immunized with OVA-coated microparticles.

OVA-specific CD8 T-cell responses after immunization with OVA-Inv-coated microparticles. To investigate whether the OVA-Inv-coated microparticles also induce CD8 T-cell responses, OVA-specific splenic T cells from transgenic OT-1 mice were adoptively transferred into C57BL/6 mice. Three days after T-cell transfer, $2 \times 10^{10}$ microparticles were injected into mice. Five days later, the frequency of transgenic CD8 T cells in splenic CD8 T cells was analyzed by flow cytometry. As depicted in Fig. 5, an increase in OVA-specific CD8 T cells could be observed upon vaccination with OVA-coated microparticles (17% OVA-specific T cells versus 10% in controls). However, a significantly higher frequency of OVA-specific T cells (30%) was found upon administration of OVA-Inv397-coated microparticles. These results show that OVA-Inv-coated microparticles induce significant OVA-specific CD8 T-cell responses in mice.

Cytokine production by OVA-specific CD8 T cells. To address the cytokine production of the expanding OVA-specific CD8 T cells, spleen cells were recovered on day 5 after immunization and cultivated for another 3 days in the presence of SIINFEKL peptide, and the supernatants were analyzed for IFN-γ by ELISA. We observed significantly increased IFN-γ production (9 ng/ml) in cultures from mice after immunization with OVA-Inv397 microparticles compared to T cells from mice after immunization with OVA microparticles (3 ng/ml) or controls (Fig. 6A). In addition, we performed intracellular staining for IFN-γ to determine the proportion of IFN-γ-producing T cells among the spleen cells. Flow cytometry analysis revealed that about 26% of OVA-specific CD8 T cells produced IFN-γ after immunization with the OVA-Inv397 microparticles whereas only 12% of these cells produced IFN-γ after immunization with OVA microparticles (Fig. 6B).

DISCUSSION

Vaccination is an important measure in the prevention of infectious diseases. Due to the low immunogenicity of many antigens, immunogenic carriers or adjuvants are required and included in a vaccine. Several microbial products have been described elsewhere as adjuvants for the induction of specific immune responses (30). Induction of antigen-specific responses to protein antigens requires the activation of T cells. In this study we investigated the potential of an outer membrane protein of Y. enterocolitica, the Inv protein, to induce OVA-specific T-cell responses in mice as this protein targets β1
integrins of host cells, resulting in activation of several signaling pathways. These signaling events confer (i) rearrangement of the actin cytoskeleton leading to, e.g., host cell internalization of \textit{Y. enterocolitica} and (ii) activation of NF-κB and mitogen-activated protein kinase leading to, e.g., IL-8 production.

We constructed a hybrid protein consisting of Inv and the model antigen OVA and applied this protein as a coating to microparticles as carriers. As the C-terminal two domains of Inv confer binding to \( \alpha_2 \beta_1 \) integrins (35), the OVA protein was fused to the N terminus of the Inv protein fragment. Herein we show in vitro that fusion of OVA to Inv did not significantly disturb the ability of Inv to promote host cell binding, internalization, and IL-8 responses. Upon exposure to HeLa cells, the microparticles coated with Inv or OVA-Inv were efficiently taken up and induced the secretion of IL-8. From these data we conclude that the OVA-Inv microparticles might exert adjuvant activity in vivo while maintaining their targeting properties for \( \beta_1 \) integrins. This was a prerequisite for the following in vivo studies by which we analyzed the influence of Inv on OVA-specific T-cell responses in an adoptive transfer model. IL-8 is a potent chemokine that binds to the chemokine receptors CXCR1 and CXCR2 (34). Recent work demonstrates that, in addition to, e.g., neutrophils, these receptors are also expressed on CD4 and CD8 T cells (38, 60, 61). Our data show that Inv-OVA-, but not OVA-coated, microparticles promote both significant CD4 and CD8 T-cell responses, suggesting that Inv acts as an adjuvant.

The classical model of antigen presentation suggests that exogenous antigens collected from the environment by phagocytosis enter the endocytic pathway which results in degradation of the antigens in phagolysosomes and their presentation via major histocompatibility complex (MHC) class II molecules to CD4 T cells (50). In contrast, endogenous cytosolic proteins may be degraded by the proteasome and translocated via transporter associated with antigen processing (TAP) transporters to the endoplasmic reticulum and are loaded onto and presented by MHC class I molecules to CD8 T cells (21). In accordance with this model we observed pronounced in vivo CD4 T-cell responses against OVA when it was fused to Inv. In fact, Inv promotes the uptake of particles via a zipper-like mechanism into host cells (28, 29). We were surprised to observe that the OVA-specific CD4 T cells produced IFN-γ as well as IL-4. This is in contrast to our previous study demonstrating that various live attenuated \( Y. enterocolitica \) mutant strains promote IFN-γ but not IL-4 production in OVA-specific T cells (15, 64). As IFN-γ is a marker for Th1 cells and IL-4 a marker for Th2 cells, it seems that Inv is able to promote the differentiation of Th0 CD4 T cells into both of these subtypes. Further studies are needed to find out whether this depends on the type of antigen or mouse strain or whether this is a feature of Inv as an adjuvant.

We could also detect pronounced OVA-specific CD8 T-cell responses upon vaccination with OVA-Inv-coated microparticles. According to the aforementioned classical model of antigen presentation, this was unexpected as Inv-triggered endocytosis should promote MHC class II-restricted antigen presentation. However, one mechanism by which this could be explained is that the microparticles may promote cross-presentation (for a review see reference 1). In fact, OVA linked to microparticles, but not soluble OVA, may be presented with MHC class I molecules upon conventional phagocytosis by macrophages (32). Moreover, phagosomes from mouse J774.1 macrophages are fully competent compartments to generate simultaneously both MHC class I- and MHC class II-restricted antigenic peptides after internalization of OVA-coated latex microparticles, and the MHC class I-restricted peptide (SIIN FEKL) rapidly exits from the phagosome to the cytosol (39). In addition, recent work demonstrated that Rac1 plays an important role in the capacity of CD8⁺ dendritic cells to endocytose apoptotic cells and prime T cells via cross-presentation (31).
The fact that Inv (via its high affinity for β1 integrins) efficiently activates Rac1 (20) may thus explain the ability of Inv-coated microparticles to induce CD8 T-cell responses by cross-presentation of OVA.

Although several new types of vaccines such as synthetic peptides or plasmid DNA with high efficacy have been developed, more-potent adjuvants are still needed. Adjuvants such as microbial proteins or carbohydrates that act as danger signals may activate antigen-presenting cells (45). Proliferative responses of CD4 as well as CD8 T cells are enhanced when an antigen is fused to bacterial flagellin or *Bordetella pertussis* adenylate cyclase CyaA, respectively, as flagellin is a ligand for TLR 5 and CyaA for the β2 integrin CD11b/CD18 (13, 54). In addition it was shown that immunization of mice with *Yersinia pestis* F1 antigen combined with flagellin as a adjuvant leads to increased anti-F1 immunoglobulin G levels and protective immunity after challenge of mice with *Y. pestis* (26). In the present study we fused an antigen to a bacterial surface component that unifies both immunostimulating and targeting properties and applied this hybrid protein as a coating to polystyrene microparticles also to take advantage of a particulate delivery system. Particulate antigen delivery systems such as microparticles increase the accessibility of antigens to the immune system. Microparticles have been demonstrated to promote the induction of cytotoxic T-lymphocyte, CD4, and antibody responses in mice (16, 36, 41, 44, 62). The immunogenicity of microparticles with adsorbed antigens has been improved by coadministration with adsorbed immunostimulatory adjuvants (58). Our results support these data and demonstrate that microparticles upon appropriate coating can in fact trigger strong CD4 and CD8 T-cell responses.

We also addressed the influence of contaminating bacterial products in the protein preparations used for coating of microparticles as these compounds (LPS and CpG DNA) may also show adjuvant activity. We determined the concentration of LPS in the protein solutions used for coating of the microparticles. The LPS concentration ranged between 50 and 100 ng per 2 × 10¹⁰ microparticles. Further attempts to reduce LPS contamination by polymyxin agarose beads were not feasible as the GST-Inv protein was removed as efficiently as LPS. Although the amounts of LPS in the recombinant protein preparations used were comparable in GST, GST-Inv, GST-Ova, and GST–OVA-Inv preparations, only the last induced significant T-cell responses, suggesting that LPS contamination did not significantly account for the profound T-cell responses of OVA-Inv-coated microparticles. Moreover, in preliminary experiments with, e.g., TLR-4-deficient mice (O. T. Bühler et al., unpublished), we were not able to differentiate between “nonspecific” (via LPS) and “specific” (via Inv) adjuvant effects exerted by microparticles.

The ability of microparticles to induce immune responses upon mucosal administration depends on their uptake into the specialized mucosa-associated lymphoid tissue (43). In this process M cells play an important role although dendritic cells may also be directly involved in antigen sampling from the gut (19, 33). For mucosal delivery, lectins have been used to target microparticles to the mucosa-associated lymphoid tissue (18, 37) and to enhance the extent of uptake of microparticles following oral delivery (27). *Yersinia* Inv has been proven to exploit β1 integrins of M cells for translocation (57). Future studies will have to demonstrate whether the microparticles coated with *Yersinia* Inv may also be used for oral vaccination. For this purpose, however, we first need to develop an appropriate formulation for oral vaccination that protects the coated microparticles from gastric acid and digestive enzymes.

Together, our results further support the idea that recom-
binant proteins fused to microbial ligands and bound to microparticles induce strong immune responses. The Inv protein of Y. enterocolitica might be particularly suitable due to its multifunctional properties including cell targeting and induction of inflammatory host responses.

FIG. 6. IFN-γ production by OVA-specific CD8+ T cells. Five days after immunization, three spleens per group were pooled. Spleen cells were prepared and stimulated with OVA257-264 (SIINFEKL) peptide (1 μg/ml). (A) Supernatants of cultures 3 days after restimulation were tested for the presence of IFN-γ by ELISA. (B) Flow cytometry analysis for intracellular IFN-γ was performed using anti-CD8-PE, anti-Vo2-FITC, and anti-IFN-γ-allophycocyanin antibody. Percentages of T cells positive for IFN-γ, OVA-specific TCR, and CD8 out of all T cells positive for IFN-γ/H9253 were prepared and stimulated with OVA 257-264 (SIINFEKL) peptide after immunization, three spleens per group were pooled. Spleen cells were tested for the presence of IFN-γ/H9253 and OVA-specific TCR, and CD8 out of all T cells positive for IFN-γ/H9253.

ACKNOWLEDGMENT

This work was supported by the Deutsche Forschungsgemeinschaft.

REFERENCES
